Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics Inc. (CNTX)
Company Research
Source: GlobeNewswire
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026. This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 (“CLDN6”) x CD3 TCE bispecific antibody currently being evaluated in CLDN6-positive tumors, including ovarian, endometrial, and testicular cancers. MSLN is a membrane protein overexp
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CNTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CNTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual MeetingGlobeNewswire
- Context Therapeutics GAAP EPS of -$0.10 misses by $0.01 [Seeking Alpha]Seeking Alpha
- Context Therapeutics (NASDAQ:CNTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
CNTX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- CNTX's page on the SEC website